BACKGROUND: CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is active in ALL. METHODS: Patients with refractory-relapsed ALL received treatment with inotuzumab. The first 49 patients received single-dose, intravenous inotuzumab at doses of 1.3 to 1.8 mg/m2 every 3 to 4 weeks. In the next 41 patients, the schedule was modified to inotuzumab weekly at a dose of 0.8 mg/m2 on day 1 and at a dose of 0.5 mg/m2 on days 8 and 15, every 3 to 4 weeks, based on higher in vitro efficacy with more frequent exposure. RESULTS: Ninety patients were treated; 68% were in salvage 2 or beyond. Overall, 17 patients (19%) achieved a complete response (CR), 27 (30%) had a CR with no platelet recovery (CRp), and 8 (9%) had a bone marrow CR (no recovery of counts), for an overall response rate of 58%. Response rates were similar for single-dose and weekly dose inotuzumab (57% vs 59%, respectively). The median survival was 6.2 months overall, 5.0 months with the single-dose schedule, and 7.3 months with the weekly dose schedule. The median survival was 9.2 months for patients in salvage 1 (37% at 1 year), 4.3 months for patients in salvage 2, and 6.6 months for patients in salvage 3 or later. The median remission duration was 7 months. Reversible bilirubin elevation, fever, and hypotension were observed less frequently on the weekly dose. In total, 36 of 90 patients (40%) underwent allogeneic stem cell transplantation. Veno-occlusive disease was noted in 6 of 36 patients after stem cell transplantation (17%), was less frequent after the weekly schedule (7%), and with less alkylators in the preparative regimen. CONCLUSIONS: Inotuzumab single-agent therapy was highly active, safe, and convenient in patients with refractory-relapsed ALL. A weekly dose schedule appeared to be equally effective and less toxic than a single-dose schedule.
BACKGROUND:CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumabozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is active in ALL. METHODS:Patients with refractory-relapsed ALL received treatment with inotuzumab. The first 49 patients received single-dose, intravenous inotuzumab at doses of 1.3 to 1.8 mg/m2 every 3 to 4 weeks. In the next 41 patients, the schedule was modified to inotuzumab weekly at a dose of 0.8 mg/m2 on day 1 and at a dose of 0.5 mg/m2 on days 8 and 15, every 3 to 4 weeks, based on higher in vitro efficacy with more frequent exposure. RESULTS: Ninety patients were treated; 68% were in salvage 2 or beyond. Overall, 17 patients (19%) achieved a complete response (CR), 27 (30%) had a CR with no platelet recovery (CRp), and 8 (9%) had a bone marrow CR (no recovery of counts), for an overall response rate of 58%. Response rates were similar for single-dose and weekly dose inotuzumab (57% vs 59%, respectively). The median survival was 6.2 months overall, 5.0 months with the single-dose schedule, and 7.3 months with the weekly dose schedule. The median survival was 9.2 months for patients in salvage 1 (37% at 1 year), 4.3 months for patients in salvage 2, and 6.6 months for patients in salvage 3 or later. The median remission duration was 7 months. Reversible bilirubin elevation, fever, and hypotension were observed less frequently on the weekly dose. In total, 36 of 90 patients (40%) underwent allogeneic stem cell transplantation. Veno-occlusive disease was noted in 6 of 36 patients after stem cell transplantation (17%), was less frequent after the weekly schedule (7%), and with less alkylators in the preparative regimen. CONCLUSIONS:Inotuzumab single-agent therapy was highly active, safe, and convenient in patients with refractory-relapsed ALL. A weekly dose schedule appeared to be equally effective and less toxic than a single-dose schedule.
Authors: N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer Journal: Hematol Oncol Clin North Am Date: 2000-12 Impact factor: 3.722
Authors: Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: D A Thomas; H Kantarjian; T L Smith; C Koller; J Cortes; S O'Brien; F J Giles; J Gajewski; S Pierce; M J Keating Journal: Cancer Date: 1999-10-01 Impact factor: 6.860
Authors: Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis J Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Hagop Kantarjian Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: David A Rizzieri; Jeffrey L Johnson; John C Byrd; Gerard Lozanski; Kristie A Blum; Bayard L Powell; Thomas C Shea; Sreenivasa Nattam; Eva Hoke; Bruce D Cheson; Richard A Larson Journal: Br J Haematol Date: 2014-01-15 Impact factor: 6.998
Authors: S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill Journal: Leukemia Date: 2015-02-27 Impact factor: 11.528
Authors: Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne Journal: Pediatr Blood Cancer Date: 2015-03-01 Impact factor: 3.167
Authors: Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson Journal: AAPS J Date: 2016-05-19 Impact factor: 4.009